Exenatide once-weekly improves metabolic parameters, endothelial dysfunction and carotid intima-media thickness in patients with type-2 diabetes: An 8-month prospective study.

Patti AM, Nikolic D, Magan-Fernandez A, Giglio RV, Castellino G, Chianetta R, Citarrella R, Corrado E, Provenzano F, Provenzano V, Montalto G, Rizvi AA, Rizzo M

Diabetes research and clinical practice10 Feb 2019Cited by 48 (Europe PMC)

PMID30759365DOI10.1016/j.diabres.2019.02.006PepBankPUB-30759365

Source link PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes, exenatide LAR reduced fasting glycaemia from baseline.
In plain wordsIn patients with type 2 diabetes, exenatide lowered fasting blood glucose from baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseFasting glycaemia
Study
n = 60
Comparator
baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 8 monthsAs given in this study (human).
Measurements
Fasting glycaemia
8.8 mmol/L
baseline
Fasting glycaemia
7.3 mmol/L
after 8 months
Source sentences
Summary
Exenatide significantly improved fasting glycaemia (from 8.8 ± 2.8 to 7.3 ± 2.2 mmol/L, p < 0.0001)
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty subjects with type 2 diabetes mellitus were treated with exenatide LAR as add-on to stable doses of metformin for 8 months in an open label study.
Report a problemFND-3075936501
02HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes, exenatide LAR reduced HbA1c from baseline.
In plain wordsIn patients with type 2 diabetes, exenatide lowered HbA1c from baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHbA1c
Study
n = 60
Comparator
baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 8 monthsAs given in this study (human).
Measurements
HbA1c
8%
baseline
HbA1c
6.9%
after 8 months
Source sentences
Summary
HbA1c (from 8.0 ± 0.4 to 6.9 ± 1.1%, p < 0.0001)
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty subjects with type 2 diabetes mellitus were treated with exenatide LAR as add-on to stable doses of metformin for 8 months in an open label study.
Report a problemFND-3075936502
03HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes, exenatide LAR reduced body mass index from baseline.
In plain wordsIn patients with type 2 diabetes, exenatide lowered body mass index from baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody mass index
Study
n = 60
Comparator
baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 8 monthsAs given in this study (human).
Measurements
Body mass index
33 kg/m<sup>2</sup>
baseline
Body mass index
31 kg/m<sup>2</sup>
after 8 months
Source sentences
Summary
body mass index (from 33 ± 9 to 31 ± 6 kg/m², p = 0.0348)
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty subjects with type 2 diabetes mellitus were treated with exenatide LAR as add-on to stable doses of metformin for 8 months in an open label study.
Report a problemFND-3075936503
04HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes, exenatide LAR reduced waist circumference from baseline.
In plain wordsIn patients with type 2 diabetes, exenatide reduced waist size from baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseWaist circumference
Study
n = 60
Comparator
baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 8 monthsAs given in this study (human).
Measurements
Waist circumference
109 cm
baseline
Waist circumference
106 cm
after 8 months
Source sentences
Summary
and waist circumference (from 109 ± 13 to 106 ± 13 cm, p = 0.0105).
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty subjects with type 2 diabetes mellitus were treated with exenatide LAR as add-on to stable doses of metformin for 8 months in an open label study.
Report a problemFND-3075936504
05HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes, the lipid profile improved significantly during exenatide LAR treatment.
In plain wordsIn patients with type 2 diabetes, blood lipid profiles improved during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
Direction not reportedLipid profile
Study
n = 60
Comparator
baseline
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · 8 monthsAs given in this study (human).
Source sentences
Summary
There was a significant improvement of the lipid profile, except in triglyceride level where no changes were observed.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty subjects with type 2 diabetes mellitus were treated with exenatide LAR as add-on to stable doses of metformin for 8 months in an open label study.
Report a problemFND-3075936505
06HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes, triglyceride levels did not change during exenatide LAR treatment.
In plain wordsIn patients with type 2 diabetes, triglycerides did not change during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeTriglycerides
Study
n = 60
Comparator
baseline
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · 8 monthsAs given in this study (human).
Source sentences
Summary
There was a significant improvement of the lipid profile, except in triglyceride level where no changes were observed.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty subjects with type 2 diabetes mellitus were treated with exenatide LAR as add-on to stable doses of metformin for 8 months in an open label study.
Report a problemFND-3075936506
07HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes, exenatide LAR reduced carotid intima-media thickness from baseline.
In plain wordsIn patients with type 2 diabetes, carotid artery wall thickness decreased from baseline during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseCarotid intima-media thickness
Study
n = 60
Comparator
baseline
Outcome group
Vascular function · Cardiovascular
Studied dose
Dose not stated · 8 monthsAs given in this study (human).
Measurements
Carotid intima-media thickness
0.98 mm
baseline
Carotid intima-media thickness
0.87 mm
after 8 months
Source sentences
Summary
Carotid IMT and flow-mediated dilation were also improved (from 0.98 ± 0.14 to 0.87 ± 0.15 mm and from 5.8 ± 1.3 to 6.8 ± 1.7%, respectively; p < 0.0001 for both).
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty subjects with type 2 diabetes mellitus were treated with exenatide LAR as add-on to stable doses of metformin for 8 months in an open label study.
Report a problemFND-3075936507
08HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes, exenatide LAR increased flow-mediated dilation from baseline.
In plain wordsIn patients with type 2 diabetes, blood vessel dilation increased from baseline during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseFlow-mediated dilation
Study
n = 60
Comparator
baseline
Outcome group
Vascular function · Cardiovascular
Studied dose
Dose not stated · 8 monthsAs given in this study (human).
Measurements
Flow-mediated dilation
5.8%
baseline
Flow-mediated dilation
6.8%
after 8 months
Source sentences
Summary
Carotid IMT and flow-mediated dilation were also improved (from 0.98 ± 0.14 to 0.87 ± 0.15 mm and from 5.8 ± 1.3 to 6.8 ± 1.7%, respectively; p < 0.0001 for both).
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty subjects with type 2 diabetes mellitus were treated with exenatide LAR as add-on to stable doses of metformin for 8 months in an open label study.
Report a problemFND-3075936508

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.